Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports

The potential of T-DXd in patients with metastatic NSCLC harboring <i>HER2</i> non-exon 19/20 mutations is considerable, which deserves to be validated in large-sample studies.

Authors

Hanhan Chen (ORCID: https://orcid.org/0000-0002-6092-6695)
Chunxia He (ORCID: https://orcid.org/0000-0001-7181-2688)
Xiaolin Liu (ORCID: https://orcid.org/0000-0002-8371-5612)
Jue Huang (ORCID: https://orcid.org/0000-0002-9984-366X)
Yanping Du (ORCID: https://orcid.org/0000-0001-7225-1923)
Yan Meng

Institutions

Guangzhou University of Chinese Medicine (CN)
Fujian Medical University (CN)
Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
Zhongshan Hospital of Xiamen University (CN)
Hainan Medical College Hospital (CN)

Publication Details

Journal: Frontiers in Immunology
Published: 2025-08-12
DOI: https://doi.org/10.3389/fimmu.2025.1631768
Citations: 1
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 1.52

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports

Hanhan Chen, Chunxia He, Xiaolin Liu, Jue Huang et al.

Aug 12, 2025

1 citations

Frontiers in Immunology

Lung Cancer Treatments and Mutations

1.52

article

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports

Hanhan Chen, Chunxia He, Xiaolin Liu, Jue Huang, Yanping Du, Yan Meng

August 12, 2025article en

1 citations

Abstract

The potential of T-DXd in patients with metastatic NSCLC harboring <i>HER2</i> non-exon 19/20 mutations is considerable, which deserves to be validated in large-sample studies.

Frontiers in ImmunologyVol. 16

Guangzhou University of Chinese Medicine (CN), Fujian Medical University (CN), Guangdong Provincial Hospital of Traditional Chinese Medicine (CN), Zhongshan Hospital of Xiamen University (CN), Hainan Medical College Hospital (CN)

Good health and well-being

Openalex Percentile: Top 15%

Lung Cancer Treatments and Mutations

1.52

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports — Hanhan Chen, Chunxia He, et al. · Frontiers in Immunology (2025) | TGRS Research Map | TGRS